Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 30

1.

Osteolytic disease in IL-6 and Myc dependent mouse model of human myeloma.

Sun F, Cheng Y, Walsh SA, Acevedo MR, Jing X, Han SS, Pisano MD, Tomasson MH, Lichtenstein AK, Zhan F, Hari P, Janz S.

Haematologica. 2019 Jun 20. pii: haematol.2019.221127. doi: 10.3324/haematol.2019.221127. [Epub ahead of print]

2.

IL-6-induced stimulation of c-myc translation in multiple myeloma cells is mediated by myc internal ribosome entry site function and the RNA-binding protein, hnRNP A1.

Shi Y, Frost PJ, Hoang BQ, Benavides A, Sharma S, Gera JF, Lichtenstein AK.

Cancer Res. 2008 Dec 15;68(24):10215-22. doi: 10.1158/0008-5472.CAN-08-1066.

3.

AKT activity determines sensitivity to mammalian target of rapamycin (mTOR) inhibitors by regulating cyclin D1 and c-myc expression.

Gera JF, Mellinghoff IK, Shi Y, Rettig MB, Tran C, Hsu JH, Sawyers CL, Lichtenstein AK.

J Biol Chem. 2004 Jan 23;279(4):2737-46. Epub 2003 Oct 23.

5.

Sulfur-containing amino acids decrease cisplatin cytotoxicity and uptake in renal tubule epithelial cell lines.

Kröning R, Lichtenstein AK, Nagami GT.

Cancer Chemother Pharmacol. 2000;45(1):43-9.

PMID:
10647500
6.

Differential effects of cisplatin in proximal and distal renal tubule epithelial cell lines.

Kröning R, Katz D, Lichtenstein AK, Nagami GT.

Br J Cancer. 1999 Jan;79(2):293-9.

7.

Suppressive factor or factors derived from head and neck squamous cell carcinoma induce apoptosis in activated lymphocytes.

Billings KR, Wang MB, Lichtenstein AK.

Otolaryngol Head Neck Surg. 1997 Apr;116(4):458-65.

PMID:
9141395
8.

Quantitative comparison of multiple myeloma tumor contamination in bone marrow harvest and leukapheresis autografts.

Vescio RA, Han EJ, Schiller GJ, Lee JC, Wu CH, Cao J, Shin J, Kim A, Lichtenstein AK, Berenson JR.

Bone Marrow Transplant. 1996 Jul;18(1):103-10.

PMID:
8832002
9.

Regulation of transforming growth factor-beta 1-mediated apoptosis in head and neck squamous cell carcinoma.

Duffey DC, Calcaterra TC, Lichtenstein AK.

Laryngoscope. 1996 Jul;106(7):889-94.

PMID:
8667989
10.

VH gene usage is multiple myeloma: complete absence of the VH4.21 (VH4-34) gene.

Rettig MB, Vescio RA, Cao J, Wu CH, Lee JC, Han E, DerDanielian M, Newman R, Hong C, Lichtenstein AK, Berenson JR.

Blood. 1996 Apr 1;87(7):2846-52.

11.

A CD10-positive subset of malignant cells is identified in multiple myeloma using PCR with patient-specific immunoglobulin gene primers.

Cao J, Vescio RA, Rettig MB, Hong CH, Kim A, Lee JC, Lichtenstein AK, Berenson JR.

Leukemia. 1995 Nov;9(11):1948-53.

PMID:
7475288
12.

Deletion of genetic material from a poly(ADP-ribose) polymerase-like gene on chromosome 13 occurs frequently in patients with monoclonal gammopathies.

Cao J, Hong CH, Rosen L, Vescio RA, Smulson M, Lichtenstein AK, Berenson JR.

Cancer Epidemiol Biomarkers Prev. 1995 Oct-Nov;4(7):759-63.

13.

Analysis of multiple myeloma third complementarity-determining regions reveals characteristics of prenatal B cells.

Kunkel LA, Vescio R, Cao J, Hong CH, Kim A, Schiller GJ, Lichtenstein AK, Berenson JR.

Ann N Y Acad Sci. 1995 Sep 29;764:519-22. No abstract available.

PMID:
7486579
14.

Myeloma Ig heavy chain V region sequences reveal prior antigenic selection and marked somatic mutation but no intraclonal diversity.

Vescio RA, Cao J, Hong CH, Lee JC, Wu CH, Der Danielian M, Wu V, Newman R, Lichtenstein AK, Berenson JR.

J Immunol. 1995 Sep 1;155(5):2487-97.

PMID:
7650379
15.
16.

Multiple myeloma clones are derived from a cell late in B lymphoid development.

Berenson JR, Vescio RA, Hong CH, Cao J, Kim A, Lee CC, Schiller G, Berenson RJ, Lichtenstein AK.

Curr Top Microbiol Immunol. 1995;194:25-33.

PMID:
7534671
17.

The hematopoietic stem cell antigen, CD34, is not expressed on the malignant cells in multiple myeloma.

Vescio RA, Hong CH, Cao J, Kim A, Schiller GJ, Lichtenstein AK, Berenson RJ, Berenson JR.

Blood. 1994 Nov 15;84(10):3283-90.

18.

Defensins: antimicrobial and cytotoxic peptides of mammalian cells.

Lehrer RI, Lichtenstein AK, Ganz T.

Annu Rev Immunol. 1993;11:105-28. Review.

PMID:
8476558
19.

Direct cytotoxicity of polymorphonuclear leukocyte granule proteins to human lung-derived cells and endothelial cells.

Okrent DG, Lichtenstein AK, Ganz T.

Am Rev Respir Dis. 1990 Jan;141(1):179-85.

PMID:
2297176
20.

Clonal rearrangement of immunoglobulin genes in the peripheral blood of multiple myeloma patients.

Berenson JR, Lichtenstein AK.

Br J Haematol. 1989 Nov;73(3):425-8. No abstract available.

PMID:
2605134
21.

Synergistic cytolysis mediated by hydrogen peroxide combined with peptide defensins.

Lichtenstein AK, Ganz T, Selsted ME, Lehrer RI.

Cell Immunol. 1988 Jun;114(1):104-16.

PMID:
2836069
22.
23.
24.
25.

Synergistic effects of combination sequential immunotherapies in a murine ovarian cancer model.

Berek JS, Lichtenstein AK, Knox RM, Jung TS, Rose TP, Cantrell JL, Zighelboim J.

Cancer Res. 1985 Sep;45(9):4215-8.

26.

Natural killer inhibitory substance produced by the peritoneal cells of patients with ovarian cancer.

Lichtenstein AK, Berek J, Zighelboim J.

J Natl Cancer Inst. 1985 Feb;74(2):349-55.

PMID:
3856049
27.
29.

Immunotherapy with biochemically dissociated fractions of Propionibacterium acnes in a murine ovarian cancer model.

Berek JS, Cantrell JL, Lichtenstein AK, Hacker NF, Knox RM, Nieberg RK, Poth T, Elashoff RM, Lagasse LD, Zighelboim J.

Cancer Res. 1984 May;44(5):1871-5.

30.

Primary mediastinal lymphoma in adults.

Lichtenstein AK, Levine A, Taylor CR, Boswell W, Rossman S, Feinstein DI, Lukes RJ.

Am J Med. 1980 Apr;68(4):509-14.

PMID:
6892753

Supplemental Content

Loading ...
Support Center